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Abstract
Background: Tumor cells are highly dependent on glucose even in the presence of oxygen. This concept called
the Warburg effect is a hallmark of cancer and strategies are considered to therapeutically exploit the phenomenon
such as ketogenic diets. The success of such strategies is dependent on a profound understanding of tumor
cell metabolism. With new techniques it is now possible to thoroughly analyze the metabolic responses to the
withdrawal of substrates and their substitution by others. In the present study we used gas chromatography
coupled to mass spectrometry (GC-MS) to analyze how glioblastoma brain tumor cells respond metabolically
when glucose is withdrawn and substituted by pyruvate.
Methods: Glioblastoma brain tumor cells were cultivated in medium with high (25 mM), medium (11 mM) or low (5.
5 mM) glucose concentration or with pyruvate (5 mM). After 24 h GC-MS metabolite profiling was performed.
Results: The abundances of most metabolites were dependent on the supply of glucose in tendency but not in a
linear manner indicating saturation at high glucose. Noteworthy, a high level of sorbitol production and release was
observed at high concentrations of glucose and high release of alanine, aspartate and citrate were observed when
glucose was substituted by pyruvate. Intermediates of the TCA cycle were present under all nutritional conditions
and evidence was found that cells may perform gluconeogenesis from pyruvate.
Conclusions: Our experiments reveal a high plasticity of glioblastoma cells to changes in nutritional supply which
has to be taken into account in clinical trials in which specific diets are considered for therapy.
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Background
In many studies published in recent years the analysis
of tumors predominately focused on gene and protein
expression as well as on signal transduction in order to
draw conclusions about the biology of cancer. Compared
to the high amount of literature focusing on these topics
much less has been investigated with regard to cancer cell
metabolism despite the fact that the peculiarities of energy
metabolism in tumors have already been investigated at
the beginning of the last century [1].
The most prominent feature of tumor cell metabolism
is the so-called Warburg effect which describes a strong
dependence on glycolytic production of ATP accompanied
by the conversion of pyruvate to lactate even in the pres-
ence of oxygen (aerobic glycolysis). In his article from
1956 which was a translation of a lecture delivered in
1955, Warburg still proposed that “respiration” (OxPhos)
must be irreversibly injured in cancer cells [2]. Although
the concept has been refined, it is still common sense that
in many cancer cell lines as well as in solid tumors the
production of lactate is more pronounced than the pro-
duction of pyruvate. Pyruvate accounts for 60–75 % of the
metabolic consumption of external glucose whereas the
production of acetyl-CoA from pyruvate accounts for ~10
to 25 % of the glycolytic flux [3, 4]. At this point it should
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also be kept in mind that only a fraction of the acetyl-CoA
produced from pyruvate is used for the production of
ATP [3, 4].
Aerobic glycolysis is still considered to be a hallmark
of cancer [5] and up to now no breakthrough thera-
peutic strategy exploiting this potential Achilles heel of
cancer has been developed. Aside from research on
drugs that could possibly be used for a “metabolic ther-
apy” (for review see [6]), several authors and clinicians
focused on the development of diets especially high in
fat and low in carbohydrates. These so-called ketogenic
diets were considered having beneficial effects by forcing
cells to utilize fatty acids as their primary energy source
[7–10]. Aside from the increasing amount of data imply-
ing that the ketogenic diet is an effective adjuvant cancer
therapy (for a summary of current mouse models and
clinical trials see [11]), the underlying mechanisms
might be more complex involving also anti-angiogenic,
anti-inflammatory and pro-apoptotic processes [12].
However, it is without question that the development of
successful strategies targeting tumor-specific metabol-
ism requires a thorough understanding of the under-
lying mechanisms, especially of the mechanisms that
enable tumor cells to switch from one substrate to an-
other under defined dietary constraints. Unfortunately,
up to now, most investigations focused on proteins re-
quired for the glycolytic flux and much research has
been committed to the analysis of their activity [6, 13].
In addition, a number of transcription factors and path-
ways involved in the up-regulation of the corresponding
genes have frequently been identified to be aberrantly
regulated in cancer such as c-Myc, Hif-1α or mTOR
[14]. Much less research has been done on the metabo-
lites and their concentration as the available methods
have been cumbersome and mostly out of fashion. With
the advent of improved technologies such as liquid or
gas chromatography (GC) coupled to mass spectrometry
(MS) the biochemical analysis of pathway fluxes and
changes of single metabolite concentrations under dif-
ferent physiological conditions became possible in an
elegant and precise manner.
In the present work we used GC coupled to MS to
analyze the metabolic response of glioblastoma cells to
the presence of different concentrations of glucose and
in a situation when glucose is substituted by pyruvate.
Glioblastoma is the most aggressive and most frequent
primary brain tumor in adults with a median survival
after biopsy and standard therapy of only 14.6 months
[15]. As previous experiments pointed towards the im-
portance of glycolysis for the survival of cells derived
from this highly malignant tumor and the possibility that
pyruvate may become important under conditions of
impaired glycolysis [16], we analyzed metabolite abun-
dances under different concentrations of glucose and in
medium in which glucose was substituted by pyruvate.
In addition, we omitted medium supplements commonly
used such as fetal bovine serum or glutamine which
significantly influence metabolic fluxes and in the case
of serum in an even undefined manner.
Methods
Chemicals and reagents
If not stated otherwise all chemicals were purchased
from Sigma-Aldrich (Taufkirchen, Germany).
Cell culture
U87 cells were originally obtained from the ATCC
(Manassas, USA) and cultured in 250 mL culture flasks
(Sarstedt AG & Co., Nümbrecht, Germany) using
DMEM/25 mM glucose, without pyruvate (Life Tech-
nologies, Darmstadt, Germany) supplemented with
10 % fetal bovine serum (FBS superior, Biochrom,
Berlin, Germany), 2 mM GlutaMAX and antibiotics
(Life Technologies) at 37 °C and 5 % CO2 in humidi-
fied air in an incubator. In order to confirm identity
over long culture periods, cells were genotyped by STR
analysis at the Genolytic GmbH (Leipzig, Germany)
using a PowerPlex® 21 System (Promega, Mannheim,
Germany) and cells were confirmed as the U87MG cell
line from the ATCC [17]. For starvation experiments,
U87 cells were seeded in 6-well plates (TPP, Trasadigen,
Switzerland) at a density of 106 cells per well in 2 mL full
supplemented DMEM (10 % FBS, GlutaMAX, antibiotics)
and incubated for 3 h before receiving fresh medium
(1 mL) without a carbon source and without GlutaMAX
and FBS (DMEM [0]). Cells were incubated for 20 h be-
fore replacing the culture medium with medium (1 mL)
containing either different concentrations of glucose or
medium without glucose but pyruvate at a concentration
of 5 mM.
Determination of extracellular lactate
After incubation, media were collected for lactate deter-
mination and cells were lysed in 200 μL lysis buffer
(77 mM K2HPO4, 23 mM KH2PO4, 0.2 % TritonX-100,
pH 7.8) and the protein content was determined using
the Pierce 660 nm Protein Assay (Thermo Scientific,
Braunschweig, Germany). For D-lactate determination
collected medium (100 μL) was evaporated to dryness
and dissolved in H2Odd (25 μL). For the determination
of L-lactate, H2Odd (20 μL) was added to collected
medium (5 μL). Then, prepared samples (20 μL) were
incubated in the wells of a black 96 well plate (Greiner
Bio One, Frickenhausen, Germany) in the presence of
enzyme mix (224 μL) consisting of 430 mM glycine,
340 mM hydrazine sulfate, 5 mM NAD and 10 U L-
lactate dehydrogenase (Megazyme, Wicklow, Ireland)
(pH 9) for L-lactate and 490 mM glycine, 200 mM
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hydrazine sulfate, 1 mM DETAPAC, 5 mM NAD and
100 U D-lactate dehydrogenase (pH 9.2) for D-lactate
(Megazyme) (final concentration for all formulations) for
90 min at room temperature. Production of NADH was
observed by fluorometric detection (excitation/ emission
= 340/ 460 nm) using a SpectraMax M5 Microplate
Reader (Molecular Devices, Biberach, Germany) [18].
A standard curve was prepared using 0.375 to 10 μg
D/L-lactate.
Determination of free MGO
U87 cells were seeded as described above. After 20 h in
medium without a carbon source and without serum,
cells received fresh medium (1 mL) supplemented with
the compounds to be tested. After 24 h of incubation,
cells were washed with ice cold washing buffer (1 mL of
100 mM Tris/HCl, pH 8.0) and then 70/30 methanol/
H2O (v/v; 430 μL) containing 1.16 mM O-(2,3,4,5,6-pen-
tafluorobenzyl)hydroxylamine (PFBHA) was instantly
added to each well. After shaking for 10 min at room
temperature, the plates were placed on a shaking incuba-
tor at 40 °C for 1 h derivatization. Afterwards, the solu-
tion was transferred into a 1.5 mL reaction vial. Then,
9 M H2SO4 (10 μL) and cyclohexane (200 μL) was added
to each sample. The solution was vortex mixed, followed
by a brief centrifugation. The upper organic phase was
transferred into a clean conical glass insert. This extrac-
tion procedure was performed three times in total. The
collected extract was evaporated to dryness using a gen-
tle stream of air, analytes were dissolved in cyclohexane
(60 μL) containing suberic acid dimethyl ester as internal
standard (cyclohexane: internal standard = 10000:1, v/v)
and analyzed by GC-MS.
GC-MS analysis of intracellular MGO samples
Free MGO from cell extracts was analyzed on an Agilent
6890 N gas chromatograph equipped with a 7683 Series
auto sampler and a 30-m J&W Fisher DB-35 ms capillary
column (250-μm I.D. and 0.25 μm film) coupled with a
5973 N mass selective detector (all modules and columns
from Agilent Technologies, Waldbronn, Germany). Sam-
ples (2 μL) were injected at 250 °C in splitless mode with
helium as carrier gas with a flow rate of 1 mL/min. Initial
GC oven temperature was set to 50 °C, held for 2 min,
then increased at a rate of 15 °C/ min up to 320 °C and
held for 10 min. The electron impact ionization source
operated at 230 °C, 70 eV and a scan range of m/z 50 to
550. For MGO quantitation, the peak area of m/z 181 of
the corresponding derivative was integrated.
Metabolic profiling via GC-MS
For the determination of extracellular metabolites,
medium (10 μL) was collected from each well and im-
mediately frozen at –80 °C until further use. For the
determination of intracellular metabolites, cells were
briefly washed with pre-cooled (4 °C) washing buffer on
ice. Immediately after washing, pre-cooled (-20 °C) metha-
nol (1 mL) was added to each well and metabolites were
extracted for 24 h on an orbital shaker at 8 °C. Then, the
extracts were transferred to 1.5 mL reaction vials and add-
itional pre-cooled (4 °C) methanol (500 μL) was used to
rinse the remaining metabolites from each well and
combined with the extract. Samples were evaporated to
dryness using a speed vac (Maxi-Dry Lyo, Heto-Holten,
Allerød, Denmark) and stored at -80 °C until further use.
Derivatization and GC-MS analyses were performed as
described previously [19]. Data evaluation was carried
out using AMDIS 2.71 [20] for peak picking and cre-
ation of a customer library of detected peaks. Quantita-
tion with Xcalibur 1.4 (Thermo Scientific) was based
on the integration of selective mass traces. Tentative
identifications were achieved by spectra comparison
with NIST14 (National Institute of Standards and
Technologies [NIST], Gaithersburg, USA) and a cus-
tomer library of reference spectra under consideration
of related Kovac retention time indices [21]. Metabolite
profiling experiments were repeated once with a similar
result, whereas representative data is presented. If not
stated otherwise, the abundance of a metabolite is de-
fined by the peak area determined from the selected
ion chromatogram of an experiment normalized to
total cellular protein (μg).
Statistical analysis
Student’s t-test was performed using the algorithm im-
plemented in Excel (Version: 14.0.7128.5000; Microsoft,
Redmond, USA) (unpaired two-sample test with unequal
variances). Principal component analysis was performed
using the Excel add-in Multibase package (Numerical
Dynamics, Japan). All experiments were carried out in
6-tuplicate.
Results
D-lactate, L-lactate and MGO production at different
concentrations of glucose and supply of pyruvate
In order to investigate how different concentrations of
glucose in the medium contribute to the glycolytic flux
in U87 glioblastoma cells, we determined the production
of L-lactate in medium with different concentrations of
glucose and in the presence of 5 mM pyruvate instead of
glucose. In addition, we also determined the production of
methylglyoxal (MGO) and D-lactate. MGO arises by non-
enzymatic elimination of phosphate from glyceraldehyde-
3-phosphate and dihydroxyacetone phosphate, two inter-
mediates of glycolysis, and is finally converted to D-lactate
by the glyoxalase system [22]. We expected to get a more
comprehensive picture of the glycolytic flux than just by
the determination of L-lactate, which only appears as long
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as glycolytic produced pyruvate is not used for the pro-
duction of acetyl-CoA. For the experiment, cells were
cultivated for 20 h in the absence of glucose and pyruvate
in medium which did not contain any glutamine source or
fetal bovine serum. Then, fresh medium was added con-
taining 25, 11 and 5.5 mM glucose or 5 mM pyruvate
without glucose, followed by incubation for 24 h. The used
concentrations of glucose are commonly employed in cell
culture experiments. With regard to physiological concen-
trations, 5 mM has to be considered as a physiological
blood concentration at starvation and 11 mM as the
blood concentration after a meal, whereas 25 mM is
only reached in diabetic conditions. Blood concentra-
tions of pyruvate are supposed to be around 0.05 mM
(0.44 mg/100 ml) in fasted individuals [23]. The ra-
tional to use an almost 100-fold higher concentration is
based on control experiments in which we determined
that at this concentration (5 mM) the relative ATP con-
centration is saturated and was comparable to that ob-
tained with all three concentrations of glucose used
(Additional file 1: Figure S1). Finally, media were collected
for the determination of extracellular D- and L-lactate. In
addition, the intracellular MGO was determined from the
cells and normalized to the total extracted protein.
As can be seen in Fig. 1, there was no significant dif-
ference neither in L/D-lactate production nor in MGO
production between cells either incubated in the pres-
ence of 25 mM or 11 mM glucose. This may indicate
that there was almost the same glycolytic flux at both
concentrations of glucose. Only when the concentration
of glucose was further decreased down to 5.5 mM, a
significant reduction was detected in the production of
L-lactate (fold change to: 0.74 ± 0.08; p < 0.05) which was
very low in the absence of glucose and the presence of
pyruvate (fold change to: 0.06 ± 0.02; p < 0.0005). Al-
though a significant reduction of MGO was observed at
a concentration of 5.5 mM glucose compared to higher
glucose concentrations (fold change in 5.5 compared to
25 mM glucose: 0.71 ± 0.09; p < 0.005) the abundance of
MGO was almost equal to the one measured in the
absence of glucose (fold change in 5 mM pyruvate
compared to 25 mM glucose: 0.63 ± 0.09; p < 0.005)
indicating that the highly reactive MGO is a poor in-
dicator of the glycolytic flux. The same holds true for
D-lactate although compared to MGO it was strongly
reduced in the absence of glucose (fold change in
5 mM pyruvate compared to 25 mM glucose: 0.12 ±
0.09; p < 0.005).
Metabolites in glioblastoma cells at different supply with
glucose and pyruvate
In order to analyze how metabolites are affected by a
different supply of glucose we analyzed the associated
metabolic changes using GC-MS profiling. Therefore,
U87 cells were cultivated as described in the previous
section and after 24 h of incubation the intra-and extra-
cellular metabolites were extracted, derivatized and ana-
lyzed by GC-MS. After automated peak deconvolution
by AMDIS, 194 peaks were manually selected and
quantified using Xcalibur. Finally, 106 metabolites were
identified by comparison of mass spectra and Kovac
retention time indices with mass spectral libraries. The
resulting relative intracellular abundances are presented
in Fig. 2 as logarithmically transformed fold-changes
compared to the samples obtained from the cells treated
with 25 mM glucose.
Among the most prominent changes associated with a
reduced supply of glucose was an expected reduction in
the amount of different mono- and disaccharides and
sugar phosphates that already became prominent when
the concentration of glucose was reduced from 25 mM
to 11 mM. In contrast to the results obtained with the
analysis of MGO and lactate in the previous section, the
metabolic profile of 11 mM glucose samples was more
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Fig. 1 D-Lactate, L-lactate and MGO production at different concentrations of glucose and in medium containing pyruvate. U87 cells were cultivated
in the presence of 5.5 mM, 11 mM, 25 mM glucose or 5 mM pyruvate in the absence of glucose. After 24 h intracellular MGO (a) as well as extracellular
D-lactate (b) and L-lactate (c) were determined. All experiments have been conducted in 6-tuplicate and statistical significance was determined
by Student’s t-test with: *: p < 0.05; **: p < 0.005; ***: p < 0.0005; ns: not significant
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similar to 5.5 mM glucose than to 25 mM glucose
samples, which was confirmed by multivariate analysis
(Additional file 2: Figure S2). Possibly, this may be re-
lated to the fact that the glycolytic flux appeared to
enter saturation from 11 mM glucose supplement on.
A complete overview of the metabolites detected and
quantified and their relation to other metabolites is
depicted in Fig. 3 (for an extended version see Add-
itional file 3: Figure S3). Based on the data presented
in Fig. 3, a number of different features of tumor me-
tabolism in U87 cells under different nutritional sup-
ply was analyzed and is presented in the following
paragraphs.
Glucose and the glycolytic flux
As can be seen in Fig. 3 the intracellular abundance of
glucose increases with increased supply, but does not
follow it in a linear manner as the intracellular abun-
dance of glucose was more than 5 times higher at an
extracellular concentration of 25 mM than at 11 mM.
We presume that the transport of glucose is mainly car-
ried out by GLUT1 as this is the main transporter in
brain [24] and we found its mRNA to be ~ 25 times
more abundantly expressed than that encoding GLUT3
or GLUT4 whereas mRNA encoding GLUT2 was almost
not present in the U87 cells used in the experiment
(Additional file 4: Figure S4a). As the Km of GLUT1 for
averageaverage
average average average
average
log2
average
averageaverage average
dihydroxyacetone-phosphate
Fig. 2 Comparative metabolic profiling of U87 cells cultivated in the presence of glucose and pyruvate. Fold changes (log2-transformed) of
intracellular metabolite abundances are indicated with regard to the highest concentration of glucose employed (25 mM; set to log2(1) = 0)
for glucose concentrations of 11 mM (11 Glc), 5.5 mM (5.5 Glc) or for medium without glucose containing 5 mM pyruvate instead (Pyr).
Identified metabolites were grouped in dependence on their metabolic role: TCA: metabolites associated with the tricarboxylic acid cycle;
lipid synthesis: metabolites associated with lipid synthesis; glycolysis: glycolytic metabolites; nucleobase/nucleotides; monosaccharides;
disaccharides; sugar phosphates; amino acids; amino acid metabolism: metabolites associated with amino acid metabolism; other: other
metabolites not unequivocally associated with the other pathways indicated. The average of the fold changes from the metabolites in each
group is indicated as “average”
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glucose is around 1.5 mM, uptake should already be sat-
urated at the lowest concentration of glucose (5.5 mM).
Consequently, phosphorylation to glucose-6-phosphate
becomes important for a continuous uptake of glucose.
This phosphorylation should be catalyzed by hexokinase
2 and hexokinase 1 which at the level of the mRNA is
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Fig. 3 Metabolic pathway of U87 cells profiling data. A combined metabolic pathway is presented, including glycolysis, the pentose-phosphate
pathway, the TCA cycle and branched chain amino acid degradation. Intracellular metabolite abundances (Fig. 2) are shown as bar diagrams
depicting the relative abundance which is the: ratio between the abundance of a metabolite (the peak area) normalized to total protein (μg)
compared to the abundance at 25 mM glucose (normalized to protein) set as 1. Direct reactions without intermediates are presented as straight
lines and reactions involving several steps are presented as dotted lines. Metabolites which were not determined are labeled in Grey. All experiments
have been conducted in 6-tuplicate and statistical significance was determined by Student’s t-test with: *: p < 0.05; **: p < 0.005; ***: p < 0.0005.
An extended version of the figure including extracellular metabolite concentrations is available in the (Additional file 2: Figure S2). Abbreviations:
GA3P: glyceraldehyde-3-phosphate; DHAP: dihydroxyacetone phosphate; Glu: glutamate; aKG: α-ketoglutarate
Oppermann et al. Nutrition & Metabolism  (2016) 13:70 Page 6 of 11
three times stronger expressed than isoform 2 as re-
vealed by qRT-PCR (Additional file 4: Figure S4b). At
this point, it is interesting to note, that in normal brain
tissue hexokinase 2 is only negligibly expressed and its
expression in glioblastoma was already considered to
contribute to the Warburg effect and the malignity of
the tumor [25].
When glucose in the medium was reduced from
25 mM to 11 mM the abundances of intracellular
glucose (fold change to: 0.22 ± 0.19; p < 0.0005) and
glucose-6-phosphate (fold change to: 0.24 ± 0.16; p <
0.05) were significantly reduced. In the case of
fructose-6-phosphate (fold change to: 0.72 ± 0.42) and
glyceraldehyde-3-phosphate (fold change to: 0.9 ± 0.13)
only weak and non-significant effects were observed.
A further reduction of glucose supply to 5.5 mM did
also not significantly reduce fructose-6-phosphate
(fold change to: 0.5 ± 0.29) and 2-phospho-glycerate
(fold change to: 0.84 ± 0.35), but we observed a signi-
ficant reduction in intracellular glucose (fold change
to: 0.15 ± 0.02; p < 0.0005), glucose-6-phosphate (fold
change to: 0.12 ± 0.08; p < 0.05) and glyceraldehyde-3-
phosphate (fold change to: 0.82 ± 0.13; p < 0.05). Com-
paring glucose concentrations 11 mM and 5.5 mM in
medium, no significant changes of the aforementioned
metabolites were detected. Therefore, it has to be
assumed that the glycolytic flux downstream from
glucose-6-phosphate is similar under the different
external glucose concentrations. As the amount of
ribose-5-phosphate was also not significantly affected
by different concentrations of extracellular glucose it
may be assumed that the pentose-phosphate pathway
has the same activity at all concentrations of glucose,
although we observed a significant reduction of
erythrose-4-phosphate comparing its amounts at
25 mM glucose and 5.5 mM (fold change to: 0.57 ±
0.11; p < 0.05).
Fructose and sorbitol
Aside from a steep raise of the intracellular abundances
of glucose and glucose-6-phosphate when the extra-
cellular concentration of glucose was increased from
11 mM to 25 mM, we also observed a significant raise
in the abundances of intracellular sorbitol (fold change
to: 2.86 ± 0.98; p < 0.005) and fructose (fold change to:
7.69 ± 9.46; p < 0.005). Moreover, raising glucose con-
centrations from 5.5 mM to 11 mM in medium also re-
sulted in a significant enhancement of sorbitol
abundances (fold change to: 2.69 ± 0.62; p < 0.05). Inter-
estingly, sorbitol produced by the cells was significantly
released into the extracellular medium whereas the
extracellular abundance of fructose did not follow its
enhanced intracellular production (Additional file 3:
Figure S3).
Glucose and the tricarboxylic acid cycle
The data presented in Fig. 3 shows that the abun-
dance of intracellular lactate (fold change in 5.5
mM compared to 25 mM glucose: 0.65 ± 0.13; p <
0.05) followed in tendency the abundance of
glyceraldehyde-3-phosphate (fold change in 5.5 com-
pared to 25 mM glucose: 0.82 ± 0.13; p < 0.05) which
is the metabolite at the entry of the second (three
carbon) part of the glycolytic pathway. Although this
appears to be in accordance with the Warburg effect,
we also observed a significant reduction (fold change)
in 5.5 mM glucose compared to 25 mM glucose in
the amounts of citrate (0.57 ± 0.17; p < 0.05), malate
0.61 ± 0.12; p < 0.005) and α-ketoglutarate (0.71 ±
0.18). This clearly indicates that at a high glucose
concentration (25 mM), glucose-derived pyruvate is
metabolized by the TCA cycle.
Metabolic flux under substitution of glucose by pyruvate:
lactate and metabolites associated with the TCA cycle
When glucose was substituted by pyruvate a strong in-
crease of the intracellular amount of pyruvate was ob-
served (5 mM pyruvate compared to 25 mM glucose:
9.85 ± 4.54; p < 0.05) which clearly indicates that the
compound is readily taken up by the tumor cells. The
high intracellular amount of pyruvate was not accom-
panied by a corresponding raise of intracellular lactate.
As the formation of lactate requires NADH +H+, that
in the presence of a glycolytic flux is produced by the
conversion of glyceraldehyde-3-phosphate to glycerate
1,3-bisphosphate, a lack of reduced NADH may be the
reason for the non-appearance of increased lactate pro-
duction in the absence of glucose. We also observed a
significantly higher abundance of the TCA cycle metab-
olites citrate (1.67 ± 0.52; p < 0.05), α-ketoglutarate
(1.76 ± 0.59; p < 0.05), succinate (2.60 ± 0.56; p < 0.005)
and malate (2.42 ± 0.46; p < 0.005) following the higher
abundance of intracellular pyruvate when glucose was
substituted by pyruvate (fold change in cells exposed to
5 mM pyruvate compared to cells exposed to 25 mM
glucose). Therefore, pyruvate in the absence of glucose
can obviously be metabolized by the TCA cycle and it
has to be expected that at least two mitochondrial
NADH +H+ producing steps (from isocitrate to α-
ketoglutarate and from α-ketoglutarate to succinyl-
CoA) are active. Provided that we found no evidence of
enhanced production of lactate in the absence of glu-
cose and high levels of intracellular pyruvate, these
reduction equivalents are most likely used for the
production of ATP by OxPhos rather than shuttled
out of the mitochondria. An intensive use of pyruvate
for the production of ATP under the extracellular
concentrations employed (5 mM) is also in accord-
ance to the observation that at this concentration
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ATP production was comparable to the production in
medium containing glucose (Additional file 1: Figure S1).
We also observed a significantly higher abundance
of extracellular citrate when glucose was substituted
by pyruvate (5 mM pyruvate compared to 25 mM
glucose: 2.01 ± 0.33; p < 0.05). Most likely this citrate
originates in the mitochondria by the reaction of
acetyl-CoA with oxaloacetate. Under normal condi-
tions this reaction precedes the export of citrate
which is then cleaved by cytosolic ATP/citric acid
lyase in order to provide acetyl-CoA for lipid synthe-
sis by the cytosolic lipid acid synthase. It may be pre-
sumed that in the absence of glucose not enough
NADPH for lipid synthesis is available which can be
gained from the pentose-phosphate pathway or from
the conversion of malate to pyruvate by malic enzyme
[EC 1.1.1.40] [26]. This notion is in contrast to the
fact that the amount of ribose-5-phosphate was still
high in the absence of glucose and the presence
of pyruvate. On the other hand, the high abundance
of malate in the presence of high concentrations of
pyruvate may indicate that its conversion to pyruvate
by malic enzyme and the associated production of
NADPH is impaired.
Metabolic flux under substitution of glucose by pyruvate:
gluconeogenesis
As pointed out in the introduction several metabolites
from the glycolytic pathway are building blocks required
for growth and proliferation of tumor cells. Therefore,
the question was whether a substitution of glucose by
pyruvate contributes to gluconeogenesis sufficient for
their supply. As demonstrated in Fig. 3, abundances of
2-phosphoglycerate (fold change to: 0.24 ± 0.24) and
fructose-6-phosphate (fold change to: 0.29 ± 0.16) were
obviously reduced, whereas reduction of abundances in
glyceraldehyde-3-phosphate (fold change to: 0.34 ± 0.1;
p < 0.0005), glycerol-3-phosphate (fold change to: 0.38 ±
0.06; p < 0.005) and erythrose-4-phosphate (fold change
to: 0.31 ± 0.1; p < 0.05) was detected as statistically
significant when glucose was substituted by pyruvate
(comparing cells exposed to 5 mM pyruvate to cells ex-
posed to 25 mM glucose). Interestingly, the abundance
of ribose-5-phosphate did not appear to be affected in a
comparable manner as the aforementioned metabolites
of the glycolytic pathway when glucose was substituted
by pyruvate. This may indicate that the gluconeogenic
pathway is active in the absence of glucose and the
presence of pyruvate [27].
Metabolic flux under substitution of glucose by pyruvate:
amino acids
Substituting glucose with pyruvate resulted in a strong
increase of alanine (significant fold change to: 4.33 ± 2.01;
p < 0.05) which is most likely catalyzed by the trans-
amination of pyruvate supplied in high amounts in the
medium. A second prominent effect was a strong raise
in the concentration of aspartate (significant fold
change to: 15.09 ± 1.62; p < 0.0005). As aspartate is
mainly synthesized by a transamination reaction from
oxaloacetate it has to be assumed that under our ex-
perimental conditions more oxaloacetate was produced
by pyruvate carboxylase than is needed for anaplerosis
and gluconeogenesis. As both amino acids are released
in significantly higher amounts into the medium (ala-
nine: fold change to: 3.51 ± 0.32; p < 0.0005; aspartate
fold change to: 9.6 ± 5.63; p < 0.05), the cells seem to
continuously loose amino groups. Although speculative,
we presume that the observed increase in the amounts of
branched chain keto acids (BCKA) such as α-keto-
isocaproate (4-Methyl-2-oxopentanoate) (fold change
compared to 25 mM glucose intracellular: 2.27 ± 1.19;
extracellular: 2.18 ± 0.13; p < 0.0005), α-keto-β-methylvale-
rate ((S)-3-Methyl-2-oxopentanoate) (fold change com-
pared to 25 mM glucose intracellular: 1.76 ± 1.09;
extracellular: 1.53 ± 0.1; p < 0.0005) and of α-keto-
isovalerate (3-Methyl-2-oxobutanoate) (fold change
compared to 25 mM glucose intracellular: 2.07 ± 1.13;
extracellular: 1.69 ± 0.09; p < 0.0005) may indicate that
the amino groups originate from transamination reac-
tions catalyzed by branched-chain amino acid (BCAA)
aminotransferase [EC:2.6.1.42] using L-leucine, L-
isoleucine and L-valine as substrates (Additional file 3:
Figure S3). This notion is supported by the observation
that BCAAs are a major source of amino groups for
transamination reactions in the brain [28].
Discussion
The central aim of this study was to obtain a more com-
prehensive understanding of the metabolic contribution
of glucose and pyruvate in tumor cells. In accordance
with the concept of Krall and Christofk [21], who
pointed out that metabolic mechanisms that are im-
perative for tumor growth may be uncovered by sub-
jecting tumor cells to nutrient limitations [29], we used
different concentrations of glucose in our experiments
and we also substituted glucose by pyruvate. The ra-
tional to use pyruvate to replace glucose goes back to
the observation that cancer cells proliferate rapidly in
the presence of exogenous pyruvate [30]. It was also
demonstrated that exogenous pyruvate is required to
sustain proliferation of both cancer and non-cancer
cells that cannot utilize oxygen [31]. In this work the
authors also propose that exogenous pyruvate may be
released by tumor adjacent cells. Although, to our
knowledge there is no experimental confirmation that
non-tumor cells can release pyruvate into the tumor
microenvironment, the high expression of monocarboxylate
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transporters (which transport lactate and pyruvate) in
many tumors has led to the assumption that tumor cells
may use these transporters for the uptake of metabolically
important molecules [30].
Analyzing the dependence of the abundance of glyco-
lytic intermediates from glucose we found no strict
linear correlation between the extracellular supply of
glucose and the abundance of glycolytic intermediates,
but there was a general tendency that most metabolites
of the glycolytic and associated pathways are more
abundant at a higher concentration of glucose than at a
lower concentration.
An interesting observation is the high increase in the
abundance of sorbitol in the medium.
The polar character of sorbitol usually should prevent
its release by diffusion, which in the case of diabetes
results in the so-called diabetic cataract [32]. As intra-
cellular sorbitol does induce osmotic stress [33] it is
tempting to speculate whether tumor cells may have
acquired mechanisms for the effective removal of
sorbitol such as the sorbitol permease described to be
present in the rabbit papillary epithelial cell line PAP-
HT25 [34]. In conclusion, we consider that the high
level of sorbitol produced under conditions of high
glucose supply and especially the ability to release
this metabolite should be studied in more detail
as it may be a possible unique target for therapeutic
intervention.
Our data clearly demonstrates that at a glucose
concentration of 25 mM glycolytically derived pyruvate
is metabolized by the TCA cycle. This may at a first
glace appear to be in contrast to the Warburg effect
but is in agreement with its present day understanding.
As pointed out by DeBerardinis et al. [35], the reduc-
tion of substrate oxidation by glioblastoma and other
tumor cells can simply be secondary to the metabolic
activities needed for biosynthesis rather than being an
impairment of oxidative metabolism. At this point it
has to be taken into account that the TCA cycle also
delivers acetyl-CoA which is required for lipid biosyn-
thesis. In fact, using the paediatric glioma cell line
SF188 DeBerardinis et al. [35] could demonstrate that
10 % of total glucose metabolism is utilized for the bio-
synthesis of fatty acids and nucleotides as well as for other
processes such as glycosylation.
In conclusion, our data demonstrates that in human
U87 glioblastoma cells, pyruvate derived from glucose
can be shuttled into the TCA cycle as previously dem-
onstrated for paediatric glioma cells [35], A549 lung
carcinoma cells [4] and rat C6 glioma cells [3]. From
our data we cannot estimate the percentage of glucose
entering the TCA cycle as we did not use isotopically
labeled glucose. This will be the next step in future ex-
periments in which we will also investigate how other
energy-rich metabolites such as ketone bodies can be
utilized as substrates for glioma cell metabolism.
More experiments are required to solve the interest-
ing question whether the high extracellular concentra-
tion of citrate, under the withdrawal of glucose and its
substitution by pyruvate, indicates that the cell pro-
duces more citrate than needed for the production of
fatty acids or whether the conversion of citrate to
acetyl-CoA and oxaloacetate is impaired as this would
finally prevent tumor cell proliferation. The high
amount of citrate released into the medium also raises
a question about anaplerosis: it should be kept in
mind that the removal of citrate and other metabolites
from the TCA cycle that are used as precursors for
biosynthetic reactions outside the mitochondria, re-
quires anaplerotic reactions that refill the pool of pre-
cursor molecules. In glioblastoma and other
transformed cell lines, glutamine is the preferred ana-
plerotic precursor when it is supplied by the medium,
contributing up to 90 % to the oxaloacetate pool [35].
As in our experiments glutamine is not supplied with
the medium, the synthesis of oxaloacetate via pyruvate
carboxylase becomes important and may compensate
the loss of glutamine-dependent anaplerosis, which is
a mechanism previously proposed by Cheng et al. who
investigated glioblastoma growth under deprivation of
glutamine [36]. A high flux of pyruvate through the
pyruvate carboxylase reaction is also in agreement
with the assumption that the cells perform gluconeo-
genesis when glucose is substituted by pyruvate in
order to provide ribose-5-phosphate (or other metabo-
lites of the glycolytic pathway). At this point it is also
interesting to note that gluconeogenesis in tumor cells
under low glucose conditions has also been reported
in lung cancer cells [27] although in this study glu-
tamine served as substrate for the gluconeogenic
pathway.
Conclusions
Overall the data in the present study demonstrates that
i) there is no strict correlation between the extracellu-
lar supply of glucose and abundance of glycolytic inter-
mediates, ii) sorbitol is highly produced and released
into the medium under high glucose supply, iii) U87
cells metabolize a significant amount of glucose derived
pyruvate in the mitochondria and iv) gluconeogenesis
is most likely activated when glucose is substituted by
pyruvate. These observations suggest a high plasticity
of glioblastoma cells to changes in nutritional supply
which should be taken into account with regard to the
prescription of special diets for the treatment of tumor
patients or when considering to use specific inhibitors
of glycolysis.
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Additional files
Additional file 1: Figure S1. Relative intracellular ATP concentration at
different concentrations of glucose and pyruvate. U87 cells were seeded
at a density of 5000 cells per well in 96 well microplates and received
medium without a carbon source and without GlutaMAX and FBS for
20 h. Then, fresh medium was added containing different concentrations
of glucose (5.5 mM, 11 mM and 25 mM), pyruvate (1 mM, 2.5 mM, 5 mM,
10 mM and 20 mM) or without any carbon source (0 mM). 24 h later the
relative intracellular ATP concentration was determined by the CellTiterGlo
Assay (for method description see Additional file 5: Methods). Results
are represented as mean and standard deviation of 6 independently
measured wells compared to the signal of 25 mM glucose set to 1.
Statistical significance was determined by Student’s t-test with: *: p <
0.05; **: p < 0.005; ***: p < 0.0005; ns: not significant. (TIF 949 kb)
Additional file 2: Figure S2. Multivariate analysis of metabolite profiles.
Principal component analysis (PCA) of metabolite profiles from U87 cells
cultivated in the presence of 5.5 mM (5.5 Glc), 11 mM (11 Glc), 25 mM
glucose (25 Glc) or 5 mM pyruvate in the absence of glucose (Pyr) for
24 h. 25 Glc and Pyr appear clearly separated from each other, whereas
11 Glc and 5.5 Glc have a similar profile separated from 25 Glc and Pyr.
PC1 includes 34.7 % of variability (responsible for separation of Pyr), PC2
16.2 % (differences between the glucose treated cells). n = 6 for each
condition, all identified metabolites were included (n = 106). (TIF 69 kb)
Additional file 3: Figure S3. Extended metabolic pathway of U87 cells
profiling data. A combined metabolic pathway is presented, including
glycolysis, the pentose-phosphate pathway, the TCA cycle and the
branched chain amino acid degradation with the subcellular
localization (mitochondrial, cytoplasm and extra cellular—methodically it
can only be distinguished between intra- and extracellular metabolites).
Intracellular metabolite abundances (Fig. 2) are shown as bar diagrams
depicting the ratio between the abundance of a metabolite (the peak area)
normalized to total protein (μg) compared to the abundance at 25 mM
glucose (normalized to protein) set to 1. The consumption of
extracellularly present metabolites was determined by the comparison
of signals obtained from medium without cells to those after incubation
with cells. Thus, a value of 0 indicates the same abundance of a metabolite
in medium with and without cells (no consumption) and a value of -1
indicates that the metabolite is completely consumed. Abundances of
metabolites released from the cells are expressed as the abundance of a
metabolite in medium after incubation compared to its abundance in
medium with 25 mM glucose set to 1. All experiments have been conducted
in 6-tuplicate and statistical significance was determined by Student’s t-test
with: *: p < 0.05; **: p < 0.005; ***: p < 0.0005. The statistical analysis for
intracellular and released metabolites was performed by comparing the
abundance of a metabolite in an experiment (11 mM or 5 mM glucose
or 5 mM pyruvate) to the abundance in 25 mM glucose. For consumed
metabolites, each metabolite’s abundance was compared to its abundance
in medium without cells. Direct reactions are presented as straight lines and
reactions involving several steps are presented as dotted lines. Metabolites
which were not determined are labeled Grey. Abbreviations: GA3P:
glyceraldehyde-3-phosphate; DHAP: dihydroxyacetone phosphate; Glu:
glutamate; aKG: α-ketoglutarate; PEP: phosphoenolpyruvate. (JPG 3880 kb)
Additional file 4: Figure S4. mRNA expression of glycolytic genes in
U87 cells. Expression of mRNA encoded by the genes GLUT1/2/3/4
(glucose transporters 1/2/3/4) (a) and HK1/2 (hexokinase 1/2) (b) in U87
cells as revealed by qRT-PCR (for method description see Additional file
5). The relative expression was determined using standard curves
normalized to the expression of TATA box binding protein (TBP). (TIF 655 kb)
Additional file 5: Methods. (DOCX 16 kb)
Abbreviations
aKG: α-ketoglutarate; BCAA: Branched-chain amino acid; BCKA: Branched
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